Treatments options for alopecia

Bibliography

• Tsuboi R, Itami S, Inui S, et al. Guidelines for the management of androgenetic alopecia. J Dermatol 2012;39(2):113-20
   PubMed Web of Science ®Google Scholar
• Mahe’ YF Michelet JF, Billoni N, et al. Androgenetic alopecia and microinflammation. Int J Dermatol 2000;39(8):576-84
   PubMed Web of Science ®Google Scholar
• Trueeb R. Is androgenetic alopecia a photoaggravated dermatosis? Dermatology 2003;207(4):343-8
   PubMed Web of Science ®Google Scholar
• Yim E, Nole KL, Tosti A. 5alpha-reductase inhibitors in androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes 2014;21(6):493-8
   PubMed Web of Science ®Google Scholar
• Mella JM, Perret MC, Manzotti M, et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 2010;146(10):1141-50
   PubMed Web of Science ®Google Scholar
• Whiting DA, Olsen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol 2003;13(2):150-60
   PubMed Web of Science ®Google Scholar
• Tang L, Bernardo O, Bolduc C, et al. The expression of insulin-like growth factor 1 in follicular dermal papillae correlates with therapeutic efficacy of finasteride in androgenetic alopecia. J Am Acad Dermatol 2003;49(2):229-33
   PubMed Web of Science ®Google Scholar
• Singh MK, Avram M. Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring? J Clin Aesthet Dermatol 2014;7(12):51-5
   PubMedGoogle Scholar
• Overstreet JW, Fuh VL, Gould J, et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol 1999;162(4):1295-300
   PubMed Web of Science ®Google Scholar
• Samplaski MK, Lo K, Grober E, Jarvi K. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril 2013;100(6):1542-6
   PubMed Web of Science ®Google Scholar
• Ramot Y, Czarnowicki T, Zlotogorski A. Finasteride induced Gynecomastia: Case report and Review of the Literature. Int J Trichology 2009;1(1):27-9
   PubMedGoogle Scholar
• Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-24
   PubMed Web of Science ®Google Scholar
• Belknap SM, Aslam I, Kiguradze T, et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol 2015. [Epub ahead of print]
   Google Scholar
• Caserini M, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther 2014;52(10):842-9
   PubMed Web of Science ®Google Scholar
• Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999;41(5Pt1):717-21
   PubMed Web of Science ®Google Scholar
• Olsen EA, Dunlap F, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002;47(3):377-85
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007;57(5):767-74
   PubMed Web of Science ®Google Scholar
• Goren A, Shapiro J, Roberts J, et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatol Ther 2015;28(1):13-16
   PubMed Web of Science ®Google Scholar
• Michelet JF, Commo S, Billoni N, et al. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol 1997;108:205-9
   PubMed Web of Science ®Google Scholar
• Tosti A, Iorizzo M, Vincenzi C. Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. Arch Dermatol 2003;139(9):1221-2
   PubMed Web of Science ®Google Scholar
• Friedman ES, Friedman PS, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol 2002;46(2):309-12
   PubMed Web of Science ®Google Scholar
• Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008;59(4):547-66
   PubMed Web of Science ®Google Scholar
• Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006;55(6):1014-23
   PubMed Web of Science ®Google Scholar
• Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol 2010;63(2):252-8
   PubMed Web of Science ®Google Scholar
• Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol 2014;70(3):489-98
   PubMed Web of Science ®Google Scholar
• Boyapati A, Sinclair R. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia. Australas J Dermatol 2013;54(1):49-51
   PubMed Web of Science ®Google Scholar
• Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat 2014;25(2):156-61
   PubMed Web of Science ®Google Scholar
• Bunagan MJK, Banka N, Shapiro J. Hair transplantation update: procedural techniques, innovations and applications. Dermatol Clin 2013;31:141-53
   PubMed Web of Science ®Google Scholar
• Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma growth factors in male pattern baldness surgery. Plast Reconstr Surg 2006;118(6):1458-66
   PubMed Web of Science ®Google Scholar
• Choi YM, Diehl JM, Levins PC. Promising alternative clinical uses of prostaglandin F2α analogs: Beyond the eyelashes. J Am Acad Dermatol 2015;4:712-16
   Web of Science ®Google Scholar
• Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol 2012;66(5):794-800
   PubMed Web of Science ®Google Scholar
• Khidhir KG, Woodward DF, Farjo NP, et al. The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias. FASEB J 2013;27(2):557-67
   PubMed Web of Science ®Google Scholar
• Safety and efficacy study of bimatoprost in the treatment of men with androgenetic alopecia. Available from: www.clinicaltrials.gov
   Google Scholar
• Kim H, Choi JW, Kim JY, et al. Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial. Dermatol Surg 2013;39(8):1177-83
   PubMed Web of Science ®Google Scholar
• Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol 2014;15(2):115-27
   PubMed Web of Science ®Google Scholar
• Avram MR, Rogers NE. The use of low-level light for hair growth: part I. J Cosmet Laser Ther 2009;11(2):110-17
   PubMed Web of Science ®Google Scholar
• Avci P, Gupta GK, Clark J, et al. Low-level laser (light) therapy for treatment of hair loss. Laser Surg Med 2014;46(2):144-51
   PubMed Web of Science ®Google Scholar
• Khatu SS, More YE, Gokhale NR, et al. Platelet-rich plasma in androgenic alopecia: myth or an effective tool. J Cutan Aesthet Surg 2014;7(2):107-10
   PubMedGoogle Scholar
• Amgar G, Bouhanna P. Autologous PRP injections in androgenic alopecia. Prime 2015;5(2):24-34
   Google Scholar
• Van Zuuren EJ, Fedorowicz Z, Carter B. Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. Br J Dermatol 2012;167(5):995-1010
   PubMed Web of Science ®Google Scholar
• Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Women Health 2013;29(5):541-56
   Google Scholar
• Blume-Peytavi U, Hillmann K, Dietz E, et al. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011;65(6):1126-34
   PubMed Web of Science ®Google Scholar
• Yip L, Sinclair R. Antiandrogen therapy for androgenetic alopecia. Expert Rev Dermatol 2006;1(2):261-9
   Google Scholar
• Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002;146(6):992-9
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003;79(1):91-5
   PubMed Web of Science ®Google Scholar
• Paradisi R, Porcu E, Fabbri R, et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother 2001;45(4):469-75
   Web of Science ®Google Scholar
• Price VH, Roberts Jl, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000;43(5Pt1):768-76
   PubMed Web of Science ®Google Scholar
• Iorizzo M, Vincenzi C, Voudouris S, et al. Finasteride treatment in female pattern hair loss. Arch Dermatol 2006;142(3):298-302
   PubMed Web of Science ®Google Scholar
• Olszewska M, Rudnika L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005;4(5):637-40
   PubMedGoogle Scholar
• Boersma IH, Oranje AP, Grimalt R, et al. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol 2014;80(6):521-5
   PubMed Web of Science ®Google Scholar
• Gonzalez ME, Cantatore-Francis J, Orlow SJ. Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. Br J Dermatol 2010;163(2):378-85
   PubMed Web of Science ®Google Scholar
• Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol 2012;166(5):916-26
   PubMed Web of Science ®Google Scholar
• Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol 2011;4:107-15
   PubMedGoogle Scholar
• Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003;49(1):96-8
   PubMed Web of Science ®Google Scholar
• Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006;20(10):1243-7
   PubMed Web of Science ®Google Scholar
• Nakajima T, Inui S, Itami S. Pulse corticosteroid therapy for alopecia areata: study of 139 patients. Dermatology 2007;215(4):320-4
   PubMed Web of Science ®Google Scholar
• Hubiche T, Léauté-Labrèze C, Taïeb A, Boralevi F. Poor long term outcome of severe alopecia areata in children treated with high dose pulse corticosteroid therapy. Br J Dermatol 2008;158(5):1136-7
   PubMed Web of Science ®Google Scholar
• Friedli A, Labarthe MP, Engelhardt E, et al. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 1998;39(4Pt 1):597-602
   PubMed Web of Science ®Google Scholar
• Sharma VK. Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol 1996;35(2):133-6
   PubMed Web of Science ®Google Scholar
• Sharma VK, Gupta S. Twice weekly 5 mg dexamethasone oral pulse in the treatment of extensive alopecia areata. J Dermatol 1999;26(9):562-5
   PubMedGoogle Scholar
• Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol 1983;63(1):49-52
   PubMed Web of Science ®Google Scholar
• Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update: part II. Treatment. J Am Acad Dermatol 2010;62(2):191-202
   PubMed Web of Science ®Google Scholar
• Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol 1998;39(5Pt1):751-61
   PubMed Web of Science ®Google Scholar
• Van der Steen PH, van Baar HM, Happle R, et al. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991;24(2Pt1):227-30
   PubMed Web of Science ®Google Scholar
• MacDonald Hull S, Pepall L, Cunliffe WJ. Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol 1991;125(2):164-8
   PubMed Web of Science ®Google Scholar
• Tosti A, Guidetti MS, Bardazzi F, Misciali C. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol 1996;35(2Pt1):199-201
   PubMed Web of Science ®Google Scholar
• Tosti A, Piraccini BM, Misciali C, Vincenzi C. Lentiginous eruption due to topical immunotherapy. Arch Dermatol 2003;139(4):544-5
   PubMed Web of Science ®Google Scholar
• Taylor CR, Hawk JL. PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years’ experience at St John’s Institute of Dermatology. Br J Dermatol 1995;133(60):914-18
   PubMed Web of Science ®Google Scholar
• Healy E, Rogers S. PUVA treatment for alopecia areata--does it work? A retrospective review of 102 cases. Br J Dermatol 1993;129(1):42-4
   PubMed Web of Science ®Google Scholar
• McMichael AJ. Excimer laser: a module of the alopecia areata common protocol. J Invest Dermatol Symp Proc 2013;16(1):S77-9
   PubMedGoogle Scholar
• Al Mutairi N. 308-nm excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol 2009;26(5):547-50
   PubMed Web of Science ®Google Scholar
• Lattouf C, Jimenez JJ, Tosti A, et al. Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol 2015;72(2):359-61
   PubMed Web of Science ®Google Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic lymphocytes and is reversed by JAK inhibition. Nat Med 2014;20(9):1043-9
   PubMed Web of Science ®Google Scholar
• Castela E, Le Duff F, Butori C, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol 2014;150(7):748-51
   PubMed Web of Science ®Google Scholar
• Trink A, Sorbellini E, Bezzola P, et al. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol 2013;169(3):690-4
   PubMed Web of Science ®Google Scholar
• Harries Mj, Sinclair RD, MacDonald-Hull S, et al. Management of primary cicatricial alopecias: options for treatment. Br J Dermatol 2008;159(1):1-22
   PubMed Web of Science ®Google Scholar
• Ramos-e-Silva M, Pirmez R. Red face revisited: Disorders of hair growth and the pilosebaceous unit. Clin Dermatol 2014;32:784-99
   PubMed Web of Science ®Google Scholar
• Meinhard J, Stroux A, Lünnemann L, et al. Lichen planopilaris: Epidemiology and prevalence of subtypes - a retrospective analysis in 104 patients. J Dtsch Dermatol Ges 2014;12(3):229-35
   PubMed Web of Science ®Google Scholar
• Tan E, Martinka M, Ball N, Shapiro J. Primary cicatricial alopecias: clinicopathology of 112 cases. J Am Acad Dermatol 2004;50(1):25-32
   PubMed Web of Science ®Google Scholar
• Kang H, Alzolibani AA, Otberg N, Shapiro J. Lichen Planopilaris. Dermatol Ther 2008;21(4):249-56
   PubMed Web of Science ®Google Scholar
• Assouly P, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg 2009;28(1):3-10
   PubMed Web of Science ®Google Scholar
• Mesinkovska NA, Tellez A, Dawes D, et al. The use of oral pioglitazone in the treatment of lichen planopilaris. J Am Acad Dermatol 2015;72(2):355-6
   PubMed Web of Science ®Google Scholar
• Stefanidou MP, Ioannidou DJ, Panayiotides JG, Tosca AD. Low molecular weight heparin: a novel alternative therapeutic approach for lichen planus. Br J Dermatol 1999;141:1040-5
   PubMed Web of Science ®Google Scholar
• Navarini A, Kolios AG, Prinz-Vavricka BM, et al. Low-dose excimer 308-nm laser for treatment of lichen planopilaris. Arch Dermatol 2011;147(11):1325-6
   PubMed Web of Science ®Google Scholar
• Tosti A, Iorizzo M, Piraccini BM, Misciali C. Frontal fibrosing alopecia in postmenopausal women. J Am Acad Dermatol 2005;52(1):55-60
   PubMed Web of Science ®Google Scholar
• Vano-Galvan S, Molina-Ruiz AM, Serrano-Falcon C, et al. Frontal fibrosing alopecia: a multicentre review of 355 patients. J Am Acad Dermatol 2014;70(4):670-8
   PubMed Web of Science ®Google Scholar
• Olsen EA. Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. J Investig Dermatol Symp Proc 2005;10(3):217-21
   PubMed Web of Science ®Google Scholar
• Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009;4
   PubMed Web of Science ®Google Scholar
• Otberg N, Kang H, Alzolibani AA, Shapiro J. Folliculitis decalvans. Dermatol Ther 2008;21(4):238-44
   PubMed Web of Science ®Google Scholar
• Vañó-Galván S, Molina-Ruiz AM, Fernández-Crehuet P, et al. Folliculitis decalvans: a multicentre review of 82 patients. J Eur Acad Dermatol Venereol 2015; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Brocard A, Dreno B. Innate immunity: a crucial target for zinc in the treatment of inflammatory dermatosis. J Eur Acad Dermatol Venereol 2011;25(10):1146-52
   PubMed Web of Science ®Google Scholar
• Meesters AA, Van der Veen JP, Wolkerstorfer A. Long-term remission of folliculitis decalvans after treatment with the long-pulsed Nd:YAG laser. J Dermatol Treat 2014;25(2):167-8
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Dissecting cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppurativa. Dermatol Online J 2014;20(5):22692
   PubMedGoogle Scholar
• Koudoukpo C, Abdennader S, Cavelier-Balloy B, et al. Dissecting cellulitis of the scalp: a retrospective study of 7 cases confirming the efficacy of oral isotretinoin. Ann Dermatol Venereol 2014;14(8-9):500-6
   Web of Science ®Google Scholar
• Miteva M, Tosti A. Treatment options for alopecia: an update, looking to the future. Expert Opin Pharmacother 2012;13(9):1271-81
   PubMed Web of Science ®Google Scholar
• Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. Expert Opin Invest Drugs 2013;22(5):573-89
   PubMed Web of Science ®Google Scholar
• Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med 2012;4(126):126ra34
   PubMed Web of Science ®Google Scholar